Long-Term Treatment With Finasteride Improves Clinical Progression of Benign Prostatic Hyperplasia in Men With an Enlarged Versus a Smaller Prostate: Data From the MTOPS Trial-Reference-Cited by-同舟云学术

Long-Term Treatment With Finasteride Improves Clinical Progression of Benign Prostatic Hyperplasia in Men With an Enlarged Versus a Smaller Prostate: Data From the MTOPS Trial

Published:2011-04 Issue:4 Volume:185 Page:1369-1373
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Kaplan Steven A.¹,Lee Jeannette Y.²,Meehan Alan G.³,Kusek John W.⁴,

Affiliation:

1. Weill Cornell Medical College, New York, New York

2. University of Arkansas for Medical Sciences, Little Rock, Arkansas

3. Merck & Co., Inc., Rahway, New Jersey

4. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference8 articles.

1. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia;McConnell;New Engl J Med,2003

2. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial;Bautista;Control Clin Trials,2003

3. AUA guideline on management of benign prostatic hyperplasia (2003);J Urol,2003

4. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater;Kaplan;J Urol,2006

5. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial;Kaplan;J Urol,2008

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. α1-adrenoceptor antagonists and 5α-reductase inhibitors for urinary tract symptoms in benign prostatic hyperplasia;Journal of Paramedic Practice;2024-02-02

2. Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5‐alpha reductase inhibitor resistance;The Prostate;2024-01-03

3. Rates of False-Negative Screening in Prostate Specific Antigen Secondary to 5-Alpha Reductase Inhibitor Usage: A Quality-Improvement Initiative;International braz j urol;2022-08

4. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5‐alpha reductase inhibitor treated human benign prostate hyperplasia patients;The Prostate;2022-07-12

5. Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia;Frontiers in Pharmacology;2020-05-08